SCHEMBL3763274

SCHEMBL3763274

CCC(C)N1CCN(C(=O)CN2CCN(c3ccc(OC)cc3OC)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
LMNA P02545 4/20 0.51
KDM4E B2RXH2 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
GAA P10253 2/20 0.51
MAPT P10636 3/20 0.47
RECQL P46063 1/20 0.47
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HTR1A P08908 1/20 0.43
MAPK1 P28482 1/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768016 0.92 ALDH1A1 (0.53) ALDH1A1LMNAKDM4ETDP1GAA
SCHEMBL3773446 0.85 GAA (0.69) ALDH1A1LMNAKDM4ETDP1GAA
SCHEMBL3767437 0.84 GFER (0.59) ALDH1A1LMNAKDM4EGAAMAPT
SCHEMBL3777366 0.82 KDM4E (0.50) ALDH1A1LMNAKDM4ETDP1MAPT
SCHEMBL3765826 0.81 LMNA (0.53) ALDH1A1LMNAKDM4EGAAMAPT
SCHEMBL19002655 0.81 MAPT (0.68) ALDH1A1LMNAKDM4ETDP1GAA
SCHEMBL3770901 0.80 ALDH1A1 (0.53) ALDH1A1KDM4ETDP1GAATSHR
SCHEMBL13006332 0.80 TSHR (0.50) ALDH1A1LMNAKDM4EMAPTHPGD
SCHEMBL3773990 0.80 ALDH1A1 (0.54) ALDH1A1KDM4ETDP1GAATSHR
SCHEMBL3768133 0.79 DPP4 (0.49) ALDH1A1LMNAKDM4ETDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885LMNA 2902/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.